Leaders from government, industry, academia and investment came together to discuss how to build on existing biotechnology successes, and ensure that biotechnology innovations reach the market at the speed required to maintain U.S. competitiveness. Countries around the world are investing heavily in biotechnology and advanced manufacturing. As competition intensifies, the United States faces a critical challenge: ensuring that industrial biotechnologies can be manufactured, scaled and...

We had a whirlwind day last week (March 26) highlighting strategies to accelerate the commercial deployment biomanufacturing in the United States. Many thanks to Novonesis , IFF , Manus , Pivot Bio , Kula Bio , Ecovative , GALY , and POET for burning up the shoe leather (and braving cherry blossom traffic). It was also great working in collaboration with the Engineering Biology Research Consortium and Federation of American Scientists to cover dozens of offices on Capitol Hill -...

The AAB joined with 32 other leaders in the U.S. biomanufacturing sector calling for the inclusion of the biotechnology provisions in the Fiscal Year 2026 National Defense Authorization Act (NDAA). The letter notes that the National Security Commission on Emerging Biotechnology (NSCEB) concluded that: "Advances in biotechnology represent a paradigm shift in how conflicts can be fought and won. The countries that seize the moment will retain or achieve superpower status. Those that fail to do...